A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
NCT ID: NCT06025110
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
9 participants
INTERVENTIONAL
2023-01-23
2025-07-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Registry for Stage 2 Type 1 Diabetes
NCT06481904
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States
NCT07260110
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
NCT03875729
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
NCT05757713
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TCD601
Administered one of three doses of TCD601 over a 12 week treatment period.
TCD601
Investigational Product
Placebo
Placebo is administered over a 12 week treatment period.
Placebo
Comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TCD601
Investigational Product
Placebo
Comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patients ≥ 18 to 45 years of age
* A diagnosis of type 1 diabetes
Exclusion Criteria
* History of cancer
* History of heart disease
* Recent infection
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ITB-Med LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fredrik Juhlin
Role: STUDY_DIRECTOR
ITB-MED
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Brussel
Brussels, , Belgium
UZ Leuven
Leuven, , Belgium
Azienda Ospedaliero-Universitaria Renato Dulbecco
Catanzaro, , Italy
San Raffaele Hospital
Milan, , Italy
Luigi Sacco Hospital
Milan, , Italy
University of Siena
Siena, , Italy
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Universitari de Bellvitge
Barcelona, , Spain
Hospital Universitari de Girona Dr. Josep Trueta
Girona, , Spain
Hospital General de Segovia
Segovia, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Hospital Clinico Universitario de Valladolid
Valladolid, , Spain
Karolinska University Hosptial
Stockholm, , Sweden
Dorset County Hospital NHS Foundation Trust
Dorchester, Dorset, United Kingdom
Liverpool University Hospitals NHS Foundation Trust
Liverpool, Merseyside, United Kingdom
University of Birmingham
Birmingham, , United Kingdom
Bradford Teaching Hospitals NHS Foundation Trust
Bradford, , United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, , United Kingdom
Ninewells Hospital
Dundee, , United Kingdom
St George's University Hospitals NHS Foundation Trust
London, , United Kingdom
Guy's and St. Thomas' NHS Foundation Trust
London, , United Kingdom
East Kent Hospitals University NHS Foundation Trust
Margate, , United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich, , United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, , United Kingdom
Northern Care Alliance NHS Foundation Trust
Salford, , United Kingdom
Swansea Bay University Health Board
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TCD601F201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.